Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Discovery of quick method for making human monoclonal antibodies against flu

Human monoclonal antibodies (mAbs) - highly specific, identical, infection-fighting proteins produced in large quantities in the lab in cell lines that are derived from a single antibody-producing cell - against influenza can be rapidly produced in the lab, according to a new report from scientists supported by the National Institutes of Health (NIH).

30 Apr 2008

Quantum rods light up pancreatic cancer cells

Quantum dots have shown promise as ultrabright contrast agents for use in a variety of cancer imaging studies. Now, a team of investigators at the Multifunctional Nanoparticles in Diagnosis and Therapy of Pancreatic Cancer Platform Partnership, headed by Paras Prasad, Ph.D., of the State University of New York at Buffalo, has shown that quantum rods may perform even better than their spherical cousins.

18 Apr 2008

Drugs in the pipeline: new therapies that could change treatment strategies

The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer, according to results from a clinical trial conducted by Boston researchers.

16 Apr 2008

Scientists create monoclonal antibody libraries against avian influenza

An international group of American and Turkish research scientists, led by Sea Lane Biotechnologies, has created the first comprehensive monoclonal antibody libraries against avian influenza (H5N1) using samples from survivors of the 2005/2006 "bird flu" outbreak in Turkey.

15 Apr 2008

Targeted therapy combo overcomes treatment resistance in liver cancer

Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines.

13 Apr 2008

Targeted therapies overcome treatment resistance in liver cancer cell lines

Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported today at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines.

13 Apr 2008

Wistar Institute shares cell lines

Cell lines developed by scientists at The Wistar Institute in Philadelphia have recently been made available to researchers around the globe through the catalog collection at the Coriell Institute for Medical Research of Camden, N.J.

26 Mar 2008

PharmAthene signs agreement to acquire biodefense vaccines business from Avecia

PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threats, and Avecia Biologics Limited, a contract manufacturer of biopharmaceuticals, has announced that the companies have entered into a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia's biodefense vaccines business.

24 Mar 2008

MedImmune advances clinical development of antibody targeting interleukin-9 in patients with asthma

MedImmune has announced that its clinical program studying an investigational treatment targeting interleukin-9 (IL-9) has advanced with the start of a new trial in patients with asthma.

19 Mar 2008

Modified virus vaccine shows promise in mouse model of breast cancer

Researchers have shown that vaccinating mice with a modified form of a virus containing proteins from breast cancer cells can kill large breast cancer tumors and tumors that have spread to the lungs.

17 Mar 2008

Cancer drug allergies

Cancer patients from the Southeastern United States who are treated with the drug cetuximab, known commercially as Erbitux, are far more likely to suffer severe allergic reactions than patients in other regions of the country.

14 Mar 2008

Researchers find cause of severe allergic reaction to cetuximab

Clinicians have been perplexed by the fact that some patients given the drug cetuximab - an immune-based therapy commonly used to treat persons diagnosed with head and neck cancer, or colon cancer - have a severe and rapid adverse reaction to the drug.

13 Mar 2008

Home test kit confirms men's post-vasectomy sterility

Technology developed at the University of Virginia could soon have a dramatic impact on male contraception practices throughout the U.S. Earlier this year, the U.S. Food and Drug Administration approved SpermCheck Vasectomy, a home test that confirms men's post-vasectomy sterility and is based on discoveries made at U.Va.

12 Mar 2008

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

4 Mar 2008

Glioblastoma multiforme responds to new treatment

One of the toughest cancers to treat effectively is glioblastoma multiforme (GBM), the most common form of primary brain cancer.

28 Feb 2008

ImClone Systems enrols first patient in clinical trial of IMC-1121B to treat liver cancer

ImClone Systems Incorporated has announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer).

26 Feb 2008

XYNTHA approved for teatment of hemophilia A by FDA

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE) , announced today that it has received approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis.

22 Feb 2008

New method for detecting HER2 breast cancer

Generations of mothers have served up chicken soup to remedy the common cold, but now the therapeutic fowl may find use in diagnosis as well.

21 Feb 2008

Study looks at safe dosages of the isotope astatine-211 for brain tumors

In a study to determine safe dosages of the isotope astatine-211 for patients with recurring brain tumors, researchers were pleasantly surprised to find that not only was the isotope's potency sufficient to kill residual cancer cells without damaging sensitive healthy brain cells, but the patients experienced longer survival rates.

4 Feb 2008

Genmab reaches milestones in Ofatumumab collaboration

The second milestone payment of the collaboration of DKK 87.2 million was triggered by treatment of the first patient in the Phase II study of ofatumumab in Diffuse Large B-Cell Lymphoma (DLBCL), which occurred in 2007.

22 Jan 2008